Prokinetic Agents Drive Growth in Gastroparesis Drugs Market

The application of prokinetic agents for symptoms such as constipation, which is a result of reduced motility in the distal gastrointestinal tract, further boosts their demand and propels the growth of the gastroparesis drugs market throughout the forecast period. Ani Pharmaceuticals provides Reglan, a formulation of metoclopramide, for treating gastroparesis in the United States. The market size is projected to increase by USD 1.42 billion between 2024 and 2028, exhibiting a CAGR of 3.69% over the forecast timeline.

Prokinetic medications are essential in treating gastroparesis, a condition marked by slow stomach emptying. Medications like metoclopramide and domperidone are favored because they can tackle the underlying cause of the issue. Although not every prokinetic agent results in a notable enhancement of stomach emptying, they are useful in relieving symptoms such as nausea, vomiting, and early fullness.

Gastroparesis is a long-term condition marked by slow stomach emptying, resulting in multiple digestive issues like nausea, vomiting, and abdominal discomfort. Neurogastrx's tradipitant shows potential as a novel therapy for gastroparesis, whereas metopimazine, deudomperidone, and metoclopramide are frequently used antiemetics for managing symptoms. Evoke Pharma and ANI Pharmaceuticals are some of the firms engaged in developing drugs for gastroparesis. Diabetes, lifestyle factors such as alcohol intake and tobacco use, along with specific medications like Erythromycin, can induce gastroparesis. Novel medications in clinical trials seek to target the root causes and enhance patient results.